Cala Health's wrist-worn stimulator improves tremor control in real-world study

A nurse holding the hands of an elderly patient
Some of the Cala Trio study participants described improvements in their ability to eat, drink and write, while 93% of patients saw at least a 50% reduction in the strength of their tremors. (Getty/Rawpixel)

Cala Health presented new real-world data showing that its watch-like wearable electric stimulation device could be effective in improving hand control in people with essential tremor.

The clinical study tracked 44 participants through their daily lives at home, unsupervised, over a period of three months. By using motion sensors to measure tremor severity before and after therapy sessions, Cala Health found that 93% of patients saw at least a 50% reduction in the strength of their tremors.

In addition, some participants also described improvements in their ability to eat, drink and write, and reported overall gains in quality of life. The study’s results were presented at the International Parkinson and Movement Disorder Society’s MDS Virtual Congress.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

"Patients with [essential tremor] often need to choose between living with tremors that negatively impact their daily lives or risk unwanted side effects from pharmacologic therapy—our mission is to change that equation and improve lives," said Kate Rosenbluth, Cala Health’s founder and chief scientific officer. 

RELATED: Cala Health secures $50M to market its tremor-treating wearable

The Cala Trio device (Cala Health)

While it is much more common, essential tremor is often mistaken for Parkinson’s disease, the company said—the difference being that those hand tremors happen with goal-directed movement, such as when a person reaches for an object, compared to Parkinson’s where tremors may occur mostly while at rest.

First approved by the FDA in 2018, Cala’s wearable technology non-invasively delivers electrical stimulation to the nerves in the wrist, designed to counteract the uneven signals being sent from the brain.

In August, the company presented data from a larger clinical study of its watch-like device, the Cala Trio, which met its primary endpoint in reducing tremor severity among 263 patients after three months.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.